Press Release Archives

      Semper Paratus Acquisition Corporation Announces Anticipated Listing of Tevogen Bio Holdings Inc. on Nasdaq   January 24, 2024   New York, NY, Jan. 24, 2024  — Semper Paratus Acquisition Corporation (“Semper Paratus”) (Nasdaq: LGST, LGSTW), a publicly-traded special purpose acquisition company, today announced that it has filed a supplement (“Prospectus Supplement”) toContinue reading “Semper Paratus Acquisition Corporation Announces Anticipated Listing of Tevogen Bio Holdings Inc. on Nasdaq”

      Tevogen Bio Inc. and Semper Paratus Acquisition Corporation Announce Effectiveness of Registration Statement for Business Combination   January 05, 2024       The pro forma equity value of the portion of the combined company attributable to Tevogen Bio Inc (“Tevogen Bio”) stockholders is an expected $1.2 billion. Tevogen Bio is anContinue reading “Tevogen Bio Inc. and Semper Paratus Acquisition Corporation Announce Effectiveness of Registration Statement for Business Combination”

  Tevogen Bio Expands Presence in Rapidly Emerging Field of Biotechnology AI: Files Patent Applications Related to AI-Driven T cell Target Identification and Receptor Engagement     December 19, 2023   WARREN, N.J. Tevogen Bio Inc. (“Tevogen Bio”) today announced filing of two provisional patent applications with the U.S. Patent and Trademark Office: AI algorithmsContinue reading “Tevogen Bio Expands Presence in Rapidly Emerging Field of Biotechnology AI: Files Patent Applications Related to AI-Driven T cell Target Identification and Receptor Engagement”

  Tevogen Bio Appoints IT Expert and Leader Mittul Mehta as Chief Information Officer and Head of Tevogen.ai Initiative     October 23, 2023   WARREN, N.J. Tevogen Bio Inc. (“Tevogen Bio”) today announced the appointment of Mittul Mehta as Chief Information Officer (CIO) and Head of Tevogen.ai, the newly launched initiative focused on harnessingContinue reading “Tevogen Bio Appoints IT Expert and Leader Mittul Mehta as Chief Information Officer and Head of Tevogen.ai Initiative”

        Tevogen Bio Introduces Tevogen.ai to Enhance Patient Accessibility and Accelerate Innovation Leveraging Artificial Intelligence   October 10, 2023   WARREN, N.J. Tevogen Bio Inc (“Tevogen Bio”) announces the inception of Tevogen.ai, a new initiative focused on harnessing the potential of artificial intelligence (AI) for the enhancement of drug discovery, development, manufacturing,Continue reading “Tevogen Bio Introduces Tevogen.ai to Enhance Patient Accessibility and Accelerate Innovation Leveraging Artificial Intelligence”

  Tevogen Bio Congratulates Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund on Being Elected to Serve as President of the Global Virus Network   October 12, 2023   WARREN, N.J. Tevogen Bio Inc. (“Tevogen Bio”) congratulates Professor Sten Vermund, MD, PhD, Chairperson of Tevogen Bio’s Innovation and Public Health Advisory Board, on beingContinue reading “Tevogen Bio Congratulates Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund on being elected to serve as President of the Global Virus Network”

      Semper Paratus Acquisition Corporation Files Registration Statement on Form S-4 in Connection with Proposed Business Combination with Tevogen Bio Inc   September 14, 2023   New York, NY, Sept. 14, 2023 – Semper Paratus Acquisition Corporation (Nasdaq: LGST) (“Semper Paratus”), a publicly traded special purpose acquisition company, today announced the filing ofContinue reading “Semper Paratus Acquisition Corporation Files Registration Statement on Form S-4 in Connection with Proposed Business Combination with Tevogen Bio Inc”

Tevogen Bio Welcomes Victor Sordillo, Renowned Global Safety Management Expert, to its Board of Directors   Victor Sordillo, PE, CSP, M.B.A., joins Tevogen Bio’s Board of Directors.   Victor Sordillo’s appointment enhances Tevogen Bio’s Board of Directors by introducing a rich breadth of thought leadership, underpinned by his extensive expertise in leadership, risk management, andContinue reading “Tevogen Bio Welcomes Victor Sordillo, Renowned Global Safety Management Expert, to its Board of Directors”

      Tevogen Bio to Become Publicly Listed on NYSE via Business Combination with Semper Paratus Acquisition Corporation   Tevogen Bio Inc. (“Tevogen Bio”) is an advanced-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology.   Founded by a consortium of top-tier biopharma executives and renownedContinue reading “Tevogen Bio to Become Publicly Listed on NYSE via Business Combination with Semper Paratus Acquisition Corporation”

      Tevogen Bio to Become Publicly Listed on NYSE via Business Combination with Semper Paratus Acquisition Corporation   Tevogen Bio Inc. (“Tevogen Bio”) is an advanced-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology.   Founded by a consortium of top-tier biopharma executives and renownedContinue reading “Tevogen Bio to Become Publicly Listed on NYSE via Business Combination with Semper Paratus Acquisition Corporation”